Articles

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Department of Hematology and Stem Cell Transplantation, University Hospital Essen
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Hospital General, Alicante
Department of Hematology and Stem Cell Transplantation, University Hospital Essen
Clinical Haematology Department, Centro Hospitalar São João, Oporto
Hospital Nord, Nurnberg
Hematology Department, Hospital San Pedro Acantara, Cáceres
Department of Internal Medicine II, University Hospital of Frankfurt Main
Hospital Central de Asturias, Oviedo
Department of Internal Medicine 5 – Hematology/Oncology, University Hospital of Erlangen
Hematology Department, Hospital Universitario Severo Ochoa, Madrid
University Hospital Muenster, Muenster
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Robert Bosch Hospital Stuttgart, Stuttgart
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Klinikum Chemnitz, Chemnitz
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen
Hospital General de Albacete
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen
Department of Internal Medicine II, University Hospital of Kiel
Fundación Jiménez Díaz, Madrid
Universitätsklinikum Würzburg, Würzburg
Hospital 12 de Octubre, Complutense University, CNIO, Madrid
Universitätsklinikum Würzburg, Würzburg
Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz
Philipps University Marburg, and University Hospital Giessen and Marburg, Marburg
Medizinische Klinik V, Sozialstiftung Bamberg, Bamberg
Friedrich Schiller University, Jena
Medical Clinic III, University Medicine Mannheim, Mannheim
Department of Hematology and Oncology, Augsburg University Hospital, Augsburg
Rems-Murr-Klinikum Winnenden, Winnenden
Department of Hematology and Oncology, Carl-Thiem-Klinikum, Cottbus, Cottbus
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig
Department of Internal Medicine II, University Hospital of Kiel
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Department of Internal Medicine II, University Hospital of Frankfurt Main
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg
Haematologica Early view Jun 9, 2022 https://doi.org/10.3324/haematol.2022.281137